A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage Therapy
Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service
First received: November 2, 1999
Last updated: June 24, 2009
Last Verified: April 2002
History of Changes
The purpose of this study is to see if it is safe and effective to give HE2000, an
experimental anti-HIV drug, to HIV-infected patients on salvage therapy (emergency treatment
used when a patient has not responded to standard therapy).
HE2000 is a hormone that is suspected to make it more difficult for HIV to live in cells.
Drug : HE2000
Primary Purpose: Treatment
|Official Title:||A Phase I/II, Open-Label Study of the Safety, Tolerance, Pharmacokinetics, Drug-Interaction and Anti-HIV Activity of Intramuscularly Administered Alpha-Epi-Br (HE2000) in HIV-Infected Patients on Salvage Therapy|
Further study details as provided by NIH AIDS Clinical Trials Information Service:
HE2000 is a synthetic steroid hormone that, when tested in the laboratory, had anti-viral
activity against wild-type and drug-resistant variants of HIV. HE2000 works through a natural
biochemical mechanism in cells to make them less able to support viral infection.
There are 4 treatment groups of increasing doses of HE2000; each group consists of 2 parts (Part A and B). Part A is a single administration of HE2000 injected intramuscularly, and Part B is 5 consecutive daily intramuscular injections of HE2000. Patients receive the same dosage throughout Parts A and B of the study. Patients are asked to return to the clinic periodically for blood sample collection. Patients may remain at the hospital overnight for pharmacokinetic evaluation. Drug safety, tolerance, efficacy, and pharmacokinetics are measured. Samples from treatment Group 4 are analyzed for specific cell function.
|Ages Eligible for Study:||18 Years and older|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Patients may be eligible for this study if they:
- Are at least 18 years old.
- Are HIV-positive.
- Have been on their current anti-HIV drug combination for at least 30 days prior to the screening visit.
- Are currently failing at least their second anti-HIV drug treatment.
- Are not responding to their current anti-HIV treatment, have failed at least 1 anti-HIV combination, and do not have many options for treatment (Groups 3 and 4 only).
- Are willing to not make any changes in their anti-HIV treatment until at least Day 50 during the study.
- Have a CD4 count of at least 100 cells/mm3 at study entry.
- Have a viral load (level of HIV in the body) between 5,000 and 250,000 copies/ml at study entry.
- Agree to use barrier methods of birth control (e.g., condoms) during the study.
- Have hepatitis B or C.
- Have been treated for cancer within 4 weeks prior to study entry, or will need to be treated during the study. (Patients with Kaposi's sarcoma are eligible but must not have received any treatment within 4 weeks before study entry or require treatment during the study.)
- Have received certain medications including those affecting the immune system.
- Are pregnant or breast-feeding.
- Have an active, serious infection, including opportunistic (AIDS-defining) infection that requires treatment during the study or during the 2 weeks prior to study entry.
- Have a condition or are receiving therapy that would prevent them from completing the
Patients will not be eligible for this study if they:
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002422
Locations Show More
|United States, California|
|Palm Springs, California, United States, 92262|
|Veterans Affairs Palo Alto Health Care Ctr|
|Palo Alto, California, United States, 94304|
|Quest Clinical Research|
|San Francisco, California, United States, 94115|
|United States, Illinois|
|Northwestern Univ Med School|
|Chicago, Illinois, United States, 60611|
|United States, New York|
|St Vincents Hosp / Clinical Research Program|
|New York, New York, United States, 10011|
|United States, Texas|
|Plaza Med Ctr|
|Houston, Texas, United States, 77004|
Sponsors and CollaboratorsHarbor Therapeutics
|Responsible Party:||Harbor Therapeutics|
|ClinicalTrials.gov Identifier:||NCT00002422 History of Changes|
|Other Study ID Numbers:||303A|
|Study First Received:||November 2, 1999|
|Last Updated:||June 24, 2009|
Keywords provided by NIH AIDS Clinical Trials Information Service:Injections, Intramuscular
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on March 22, 2018
This information is provided by ClinicalTrials.gov.